Live prices from 7 UK suppliers, from £49.00, compared side by side so you never overpay.
Copy the code — you'll paste it at checkout.
with our exclusive code
You're about to visit an external supplier
with our exclusive code
By clicking "Continue", you acknowledge that you understand and accept the above. Read our full disclosure.
Compare 1 price for Teriparatide. Cheapest: £80.00. Average: £80.00.
| Compare | Visit | |||||||
|---|---|---|---|---|---|---|---|---|
| £80.00 | £8.00/mg | In Stock | Free |
Lab Tested
|
— |
More ways to compare Teriparatide
Different views of the same live UK pricing, tuned for how you like to shop.
Compare another peptide
All purchases are made directly from third-party suppliers; your relationship is solely with them. We accept no liability for the quality, purity, or legality of any products listed.
We may earn a commission when you click through to a supplier and make a purchase. This does not affect pricing information displayed.
By using this site you accept responsibility for ensuring purchases comply with applicable laws in your jurisdiction. Read our full disclosure.
PTH(1-34) | Bone-Building Anabolic Peptide
Teriparatide is an FDA-approved anabolic bone-building agent consisting of the first 34 amino acids of parathyroid hormone. Unlike antiresorptive osteoporosis drugs that slow bone loss, teriparatide actively stimulates new bone formation. The key to its mechanism is intermittent exposure: while continuous PTH causes bone resorption, daily injections stimulate osteoblasts more than osteoclasts, resulting in net bone formation. Clinical trials show 8% spine bone density increases and 65% reduction in vertebral fractures.
Teriparatide binds to PTH type 1 receptors (G-protein coupled receptors) on osteoblasts, osteocytes, and renal tubular cells. This activates PKA and PKC signaling pathways that promote osteoblast activity. The intermittent daily dosing creates an 'anabolic window' where bone formation exceeds resorption. Teriparatide upregulates IGF-1 and FGF2 expression, stimulates bone formation on trabecular and cortical surfaces, and increases bone mineral density through preferential osteoblast stimulation.
N-terminal 1-34 of parathyroid hormone
FDA-approved for women with osteoporosis at high risk of fracture.
FDA-approved for men with primary or hypogonadal osteoporosis at high risk.
FDA-approved for men and women with osteoporosis from sustained corticosteroid use.
Research interest in accelerating fracture healing and bone repair.
Investigated for jawbone regeneration in dental applications.
Teriparatide is administered as a once-daily subcutaneous injection, typically in the thigh or abdomen. It comes in pre-filled pen devices (Forteo) containing a 28-day supply. Treatment is typically limited to 2 years due to theoretical bone cancer risk from long-term use (seen only in rats at high doses).
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Osteoporosis treatment | 20 mcg | Once daily | SubQ (thigh or abdomen) |
Antiresorptive agents often needed after teriparatide to maintain bone gains. Can be used sequentially.
Adequate calcium and vitamin D intake recommended during teriparatide therapy.
Different mechanisms; no known interactions.
Different mechanisms; no known interactions.
Bone formation begins; spine BMD increases
Continued bone density improvements
5-9% spine BMD increase; fracture risk reduction
Maximum benefits achieved; transition to maintenance
StatPearls (NCBI Bookshelf)
Intermittent PTH exposure induces bone formation more than resorption; FDA-approved for osteoporosis.
PubMed
Spine BMD increased 5.9% (20mcg) and 9.0% (40mcg); femoral neck increased 1.5-2.9%.
Journal of Bone and Mineral Research
Reduced vertebral fractures by 65% and nonvertebral fractures by 35% after 20 months.
Women's Health
Initial formation without resorption creates 'anabolic window' for rapid bone volume increase.
Be the first to know when prices drop on your favourite peptides
No spam. Unsubscribe anytime. We respect your privacy.